Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akers Biosciences, Inc.    AKER

AKERS BIOSCIENCES, INC.

(AKER)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AKERS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Akers Biosciences, Inc. - AKER

12/03/2020 | 01:17pm EST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Biosciences, Inc. (NasdaqCM: AKER) with MyMD Pharmaceuticals, Inc., pursuant to which Akers shareholders will end up owning just 20% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-aker/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2020
All news about AKERS BIOSCIENCES, INC.
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..
BU
2020AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..
BU
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2020AKERS BIOSCIENCES : Entry into a Material Definitive Agreement, Unregistered Sal..
AQ
More news
Financials (USD)
Sales 2019 1,58 M - -
Net income 2019 -3,89 M - -
Net cash 2019 9,68 M - -
P/E ratio 2019 -0,50x
Yield 2019 -
Capitalization 25,3 M 25,3 M -
EV / Sales 2018 5,19x
EV / Sales 2019 -3,83x
Nbr of Employees 12
Free-Float 84,1%
Chart AKERS BIOSCIENCES, INC.
Duration : Period :
Akers Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKERS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Christopher C. Schreiber President & Chief Executive Officer
Joshua Nathaniel Silverman Chairman
Stuart Benson Chief Financial Officer
Bill Joe White Independent Non-Executive Director
Robert C. Schroeder Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AKERS BIOSCIENCES, INC.43.22%25
ABBOTT LABORATORIES3.06%193 340
MEDTRONIC PLC-0.48%156 919
BECTON, DICKINSON AND COMPANY3.41%75 258
HOYA CORPORATION-4.52%48 809
ALIGN TECHNOLOGY, INC.-0.06%42 112